Le Lézard
Classified in: Science and technology
Subject: Personnel

POSaBIT Appoints Louis Camhi to Board of Directors


POSaBIT is happy to welcome Louis Camhi to its board. Mr. Camhi brings significant experience in capital markets, public companies, payment processing, investment banking and SPACs to the POSaBIT team.

Louis Camhi is an investor in both private and public companies. Previously, he worked as an analyst at Citadel where he managed an equity long short portfolio focused on payments and financial technology companies. Prior to Citadel, Mr. Camhi worked as a senior analyst at Three Corner Global, a fundamental long short equity hedge fund and he began his career as an investment banker in the mergers and acquisitions group at Credit Suisse Group AG (NYSE:MKTS CS). Mr. Camhi received his Bachelor of Science in Finance and Accounting from the Leonard N. Stern School of Business at New York University.

ABOUT POSABIT

POSaBIT (CSE: PBIT) is a financial technology company that delivers unique and innovative, blockchain-enabled payment processing and point-of-sale systems for cash-only businesses. POSaBIT specializes in resolving pain points for complex, high-risk, emerging industries like cannabis with an all-in-one solution that is compliant, user-friendly and utilizes top-of-the-line hardware. POSaBIT's unique solution provides a safer and transparent environment for merchants while creating a better overall experience for the consumer. For additional information, visit: www.posabit.com.


These press releases may also interest you

at 08:25
Aurion Biotech, whose mission is to restore vision to millions of patients with life-changing regenerative therapies, today announced that it has dosed the first Canadian subject in its Phase 1 / 2 clinical trial (ABA-1, CLARA) of AURN001, a cell...

at 08:20
The "Highly Potent API Market - A Global and Regional Analysis: Focus on Type, Type of Synthesis, Therapeutic Area, Type of Manufacturing, End User, and Country - Analysis and Forecast, 2023-2033" report has been added to ResearchAndMarkets.com's...

at 08:15
Keysight Technologies , today announced its intention to acquire the entire issued and to be issued share capital of Spirent Communications PLC (London Stock Exchange Symbol: SPT) ("Spirent") for a cash consideration of 199 pence per Spirent share...

at 08:15
VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announces that it will be attending the LSX World Congress (29-30 April) and presenting at Bio?quity Europe (12-14 May). The...

at 08:15
Azura Ophthalmics Ltd., a clinical-stage biopharmaceutical company developing a potential new therapeutic class of Ophthalmic Keratolytics for ocular surface diseases, today announced multiple presentations highlighting positive efficacy and safety...

at 08:15
Nuvation Bio Inc. , a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced the appointment of Colleen Sjogren as Chief Commercial Officer. Ms....



News published on and distributed by: